In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin

Isabella Russo, Monica Traversa, Katia Bonomo, Alessandro De Salve, Luigi Mattiello, Paola Del Mese, Gabriella Doronzo, Franco Cavalot, Mariella Trovati, Giovanni Anfossi

Research output: Contribution to journalArticle

Abstract

Central obesity shows impaired platelet responses to the antiaggregating effects of nitric oxide (NO), prostacyclin, and their effectorsguanosine 3′,5′-cyclic monophosphate (cGMP) and adenosine 3′,5′- cyclic monophosphate (cAMP). The influence of weight loss on these alterations is not known. To evaluate whether a diet-induced body-weight reduction restores platelet sensitivity to the physiological antiaggregating agents and reduces platelet activation in subjects affected by central obesity, we studied 20 centrally obese subjects before and after a 6-month diet intervention aiming at reducing body weight by 10%, by measuring (i) insulin sensitivity (homeostasis model assessment of insulin resistance (HOMA IR)); (ii) plasma lipids; (iii) circulating markers of inflammation of adipose tissue and endothelial dysfunction, and of platelet activation (i.e., soluble CD-40 ligand (sCD-40L) and soluble P-selectin (sP-selectin)); (iv) ability of the NO donor sodium nitroprusside (SNP), the prostacyclin analog Iloprost and the cyclic nucleotide analogs 8-bromoguanosine 3′,5′-cyclic monophosphate (8-Br-cGMP) and 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) to reduce platelet aggregation in response to adenosine-5-diphosphate (ADP); and (v) ability of SNP and Iloprost to increase cGMP and cAMP. The 10 subjects who reached the body-weight target showed significant reductions of insulin resistance, adipose tissue, endothelial dysfunction, and platelet activation, and a significant increase of the ability of SNP, Iloprost, 8-Br-cGMP, and 8-Br-cAMP to reduce ADP-induced platelet aggregation and of the ability of SNP and Iloprost to increase cyclic nucleotide concentrations. No change was observed in the 10 subjects who did not reach the body-weight target. Changes of platelet function correlated with changes of HOMA IR. Thus, in central obesity, diet-induced weight loss reduces platelet activation and restores the sensitivity to the physiological antiaggregating agents, with a correlation with improvements in insulin sensitivity.

Original languageEnglish
Pages (from-to)788-797
Number of pages10
JournalObesity
Volume18
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Abdominal Obesity
Iloprost
Epoprostenol
Platelet Activation
Insulin Resistance
Nitroprusside
Weight Loss
Nitric Oxide
Blood Platelets
Body Weight
Cyclic Nucleotides
Platelet Aggregation
Adenosine Diphosphate
Adipose Tissue
Homeostasis
Reducing Diet
Diet
P-Selectin
Nitric Oxide Donors
Cyclic AMP

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Russo, I., Traversa, M., Bonomo, K., De Salve, A., Mattiello, L., Del Mese, P., ... Anfossi, G. (2010). In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity, 18(4), 788-797. https://doi.org/10.1038/oby.2009.302

In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. / Russo, Isabella; Traversa, Monica; Bonomo, Katia; De Salve, Alessandro; Mattiello, Luigi; Del Mese, Paola; Doronzo, Gabriella; Cavalot, Franco; Trovati, Mariella; Anfossi, Giovanni.

In: Obesity, Vol. 18, No. 4, 04.2010, p. 788-797.

Research output: Contribution to journalArticle

Russo, I, Traversa, M, Bonomo, K, De Salve, A, Mattiello, L, Del Mese, P, Doronzo, G, Cavalot, F, Trovati, M & Anfossi, G 2010, 'In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin', Obesity, vol. 18, no. 4, pp. 788-797. https://doi.org/10.1038/oby.2009.302
Russo I, Traversa M, Bonomo K, De Salve A, Mattiello L, Del Mese P et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity. 2010 Apr;18(4):788-797. https://doi.org/10.1038/oby.2009.302
Russo, Isabella ; Traversa, Monica ; Bonomo, Katia ; De Salve, Alessandro ; Mattiello, Luigi ; Del Mese, Paola ; Doronzo, Gabriella ; Cavalot, Franco ; Trovati, Mariella ; Anfossi, Giovanni. / In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. In: Obesity. 2010 ; Vol. 18, No. 4. pp. 788-797.
@article{f7e9af5b45b948ecbcd10970b1c913d0,
title = "In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin",
abstract = "Central obesity shows impaired platelet responses to the antiaggregating effects of nitric oxide (NO), prostacyclin, and their effectorsguanosine 3′,5′-cyclic monophosphate (cGMP) and adenosine 3′,5′- cyclic monophosphate (cAMP). The influence of weight loss on these alterations is not known. To evaluate whether a diet-induced body-weight reduction restores platelet sensitivity to the physiological antiaggregating agents and reduces platelet activation in subjects affected by central obesity, we studied 20 centrally obese subjects before and after a 6-month diet intervention aiming at reducing body weight by 10{\%}, by measuring (i) insulin sensitivity (homeostasis model assessment of insulin resistance (HOMA IR)); (ii) plasma lipids; (iii) circulating markers of inflammation of adipose tissue and endothelial dysfunction, and of platelet activation (i.e., soluble CD-40 ligand (sCD-40L) and soluble P-selectin (sP-selectin)); (iv) ability of the NO donor sodium nitroprusside (SNP), the prostacyclin analog Iloprost and the cyclic nucleotide analogs 8-bromoguanosine 3′,5′-cyclic monophosphate (8-Br-cGMP) and 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) to reduce platelet aggregation in response to adenosine-5-diphosphate (ADP); and (v) ability of SNP and Iloprost to increase cGMP and cAMP. The 10 subjects who reached the body-weight target showed significant reductions of insulin resistance, adipose tissue, endothelial dysfunction, and platelet activation, and a significant increase of the ability of SNP, Iloprost, 8-Br-cGMP, and 8-Br-cAMP to reduce ADP-induced platelet aggregation and of the ability of SNP and Iloprost to increase cyclic nucleotide concentrations. No change was observed in the 10 subjects who did not reach the body-weight target. Changes of platelet function correlated with changes of HOMA IR. Thus, in central obesity, diet-induced weight loss reduces platelet activation and restores the sensitivity to the physiological antiaggregating agents, with a correlation with improvements in insulin sensitivity.",
author = "Isabella Russo and Monica Traversa and Katia Bonomo and {De Salve}, Alessandro and Luigi Mattiello and {Del Mese}, Paola and Gabriella Doronzo and Franco Cavalot and Mariella Trovati and Giovanni Anfossi",
year = "2010",
month = "4",
doi = "10.1038/oby.2009.302",
language = "English",
volume = "18",
pages = "788--797",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin

AU - Russo, Isabella

AU - Traversa, Monica

AU - Bonomo, Katia

AU - De Salve, Alessandro

AU - Mattiello, Luigi

AU - Del Mese, Paola

AU - Doronzo, Gabriella

AU - Cavalot, Franco

AU - Trovati, Mariella

AU - Anfossi, Giovanni

PY - 2010/4

Y1 - 2010/4

N2 - Central obesity shows impaired platelet responses to the antiaggregating effects of nitric oxide (NO), prostacyclin, and their effectorsguanosine 3′,5′-cyclic monophosphate (cGMP) and adenosine 3′,5′- cyclic monophosphate (cAMP). The influence of weight loss on these alterations is not known. To evaluate whether a diet-induced body-weight reduction restores platelet sensitivity to the physiological antiaggregating agents and reduces platelet activation in subjects affected by central obesity, we studied 20 centrally obese subjects before and after a 6-month diet intervention aiming at reducing body weight by 10%, by measuring (i) insulin sensitivity (homeostasis model assessment of insulin resistance (HOMA IR)); (ii) plasma lipids; (iii) circulating markers of inflammation of adipose tissue and endothelial dysfunction, and of platelet activation (i.e., soluble CD-40 ligand (sCD-40L) and soluble P-selectin (sP-selectin)); (iv) ability of the NO donor sodium nitroprusside (SNP), the prostacyclin analog Iloprost and the cyclic nucleotide analogs 8-bromoguanosine 3′,5′-cyclic monophosphate (8-Br-cGMP) and 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) to reduce platelet aggregation in response to adenosine-5-diphosphate (ADP); and (v) ability of SNP and Iloprost to increase cGMP and cAMP. The 10 subjects who reached the body-weight target showed significant reductions of insulin resistance, adipose tissue, endothelial dysfunction, and platelet activation, and a significant increase of the ability of SNP, Iloprost, 8-Br-cGMP, and 8-Br-cAMP to reduce ADP-induced platelet aggregation and of the ability of SNP and Iloprost to increase cyclic nucleotide concentrations. No change was observed in the 10 subjects who did not reach the body-weight target. Changes of platelet function correlated with changes of HOMA IR. Thus, in central obesity, diet-induced weight loss reduces platelet activation and restores the sensitivity to the physiological antiaggregating agents, with a correlation with improvements in insulin sensitivity.

AB - Central obesity shows impaired platelet responses to the antiaggregating effects of nitric oxide (NO), prostacyclin, and their effectorsguanosine 3′,5′-cyclic monophosphate (cGMP) and adenosine 3′,5′- cyclic monophosphate (cAMP). The influence of weight loss on these alterations is not known. To evaluate whether a diet-induced body-weight reduction restores platelet sensitivity to the physiological antiaggregating agents and reduces platelet activation in subjects affected by central obesity, we studied 20 centrally obese subjects before and after a 6-month diet intervention aiming at reducing body weight by 10%, by measuring (i) insulin sensitivity (homeostasis model assessment of insulin resistance (HOMA IR)); (ii) plasma lipids; (iii) circulating markers of inflammation of adipose tissue and endothelial dysfunction, and of platelet activation (i.e., soluble CD-40 ligand (sCD-40L) and soluble P-selectin (sP-selectin)); (iv) ability of the NO donor sodium nitroprusside (SNP), the prostacyclin analog Iloprost and the cyclic nucleotide analogs 8-bromoguanosine 3′,5′-cyclic monophosphate (8-Br-cGMP) and 8-bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) to reduce platelet aggregation in response to adenosine-5-diphosphate (ADP); and (v) ability of SNP and Iloprost to increase cGMP and cAMP. The 10 subjects who reached the body-weight target showed significant reductions of insulin resistance, adipose tissue, endothelial dysfunction, and platelet activation, and a significant increase of the ability of SNP, Iloprost, 8-Br-cGMP, and 8-Br-cAMP to reduce ADP-induced platelet aggregation and of the ability of SNP and Iloprost to increase cyclic nucleotide concentrations. No change was observed in the 10 subjects who did not reach the body-weight target. Changes of platelet function correlated with changes of HOMA IR. Thus, in central obesity, diet-induced weight loss reduces platelet activation and restores the sensitivity to the physiological antiaggregating agents, with a correlation with improvements in insulin sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=77950189188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950189188&partnerID=8YFLogxK

U2 - 10.1038/oby.2009.302

DO - 10.1038/oby.2009.302

M3 - Article

C2 - 19834474

AN - SCOPUS:77950189188

VL - 18

SP - 788

EP - 797

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 4

ER -